What It Takes to Hit the 30-Day Turnaround: Optimizing the Manufacturing Workflow for mRNA Based PCVs to Deliver Rapid & Regulator-Ready Batches

• Streamlining mRNA manufacturing workflows to reduce IVT, LNP, Purification cycle time, and manual intervention

• Optimizing Phase II manufacturing operations to support a smooth transition to latestage readiness with improved repeatability, regulatory alignment, and trial scalability

• Operationalizing real-time analytics, digital batch release, and platform-based regulatory strategies across end-to-end manufacturing

Speakers:

Michelle Brown

Vice President, Portfolio Development, Oncology

Moderna